Leukemia is a malignant cancerous condition of hematopoietic stem cells associated with increased number of white blood cells within the blood circulation and bone marrow. We aimed to assess the clinical feasibility of immunotherapy for treating acute leukemia. The innate immune response provides the first line of defense for the body; whereas, adaptive immune response is recognized as a separate aberration, associated with the cancer cells. The process of immunotherapy is divided into seven different types of therapies including; monoclonal antibody therapy, vaccination, chimeric antigen receptors, radio-immunotherapy, cytokine therapy, donor lymphocyte infusion, and stem cell transplantation. However, the general treatment of leukemia involves allogeneic bone marrow transplantation, post-induction therapy, and autologous bone marrow transplantation. The study has concluded that immunotherapy depicts promising outcomes in treating acute leukemia.
To cite this article
Clinical feasibility of immunotherapy for acute leukemia – a review
5 (4): e1176
Submission date: 11 Aug 2018
Revised on: 03 Sep 2018
Accepted on: 20 Sep 2018
Published online: 04 Dec 2018
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.